Historical Information

BASKING RIDGE, N.J. (March 11, 2019)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic

BASKING RIDGE, N.J. (February 13, 2019)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple development programs targeting select cardiovascular indications and autoimmune disease, today

BASKING RIDGE, N.J. (February 5, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune disease, announced today

LA JOLLA, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- DrugCendR Inc., a clinical-stage biopharmaceutical company dedicated to developing next generation cancer therapies designed to overcome the barriers of drug delivery in solid tumors, reported today positive progress with its ongoing pancreatic

Caladrius Biosciences to Participate in Upcoming January Conferences BASKING RIDGE, N.J. (January 7, 2019)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple technology platforms targeting

BASKING RIDGE, N.J. (November 9, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announced today that management will

Development programs remain on track accompanied by c ontinued strong fiscal management. Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (November 8, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development

BASKING RIDGE, N.J. (November 8, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune disease, announces today

BASKING RIDGE, N.J. (November 2, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces that the Company will

Caladrius Biosciences to Participate in Upcoming October Conferences Company Receives “Buzz of BIO” Award at the 2018 BIO Investor Forum BASKING RIDGE, N.J. (September 27, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical